Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Carisma Therapeutics Inc. (SESN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "CARISMA THERAPEUTICS INC. Unaudited Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 76,353 $ 24,194 Marketable securities 40,725 27,802 Prepaid expenses and other assets 5,122 2,596 Total current assets 122,200 54,592 Property and equipment, net 7,590 8,628 Right of use assets – operating leases 3,047 4,822 Restricted cash 30 — Deferred financing costs 146 4,111 Total assets $ 133,013 $ 72,153 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 2,487 $ 1,728 Accrued expenses 9,614 10,361 Deferred revenue 1,416 2,459 Operating lease liabilities 2,486 3,437 Finance lease liabilities 1,215 1,162 Other current liabilities 755 523 Total current liabilities 17,973 19,670 Deferred ..."
06/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "An amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 350,000,000 was approved",
"CARISMA THERAPEUTICS INC. AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN"
05/12/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "    AMENDED AND RESTATED OPEN MARKET SALE AGREEMENT SM   May 12, 2023",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3"
05/12/2023 8-K Quarterly results
Docs: "CARISMA THERAPEUTICS INC. Unaudited Consolidated Balance Sheets March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 62,777 $ 24,194 Marketable securities 76,190 27,802 Prepaid expenses and other assets 5,535 2,596 Total current assets 144,502 54,592 Property and equipment, net 8,107 8,628 Right of use assets – operating leases 3,493 4,822 Restricted cash 30 — Deferred financing costs — 4,111 Total assets $ 156,132 $ 72,153 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 4,614 $ 1,728 Accrued expenses 10,187 10,361 Deferred revenue 2,136 2,459 Operating lease liabilities 2,597 3,437 Finance lease liabilities 1,188 1,162 Other current liabilities 755 523 Total current liabilities 21,477 19,670 Deferred ..."
04/04/2023 8-K/A Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of Independent Registered Public Accounting Firm",
"Carisma Therapeutics Inc. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Financial Statements Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets, December 31, 2022 and 2021 F-3 Consolidated Statements of Operations and Comprehensive Loss, Years Ended December 31, 2022 and 2021 F-4 Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit, Years ended December 31, 2022 and 2021 F-5 Consolidated Statements of Cash Flows, Years ended December 31, 2022 and 2021 F-6 Notes to Consolidated Financial Statements F-7 F- 1 Report of Independent Registered Public Accounting Firm",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On March 7, 2023, Sesen Bio consummated the merger with Carisma in accordance with the terms of the Agreement and Plan of Merger Reorganization, dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 by and among Carisma and Seahawk Merger Sub, Inc. , pursuant to which, among other matters, Merger Sub merged with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of Sesen Bio and the surviving corporation of the Merger. At which time, Sesen Bio changed its name to “Carisma Therapeutics Inc” . Immediately prior to the execution and delivery of the Merger Agreement, Carisma entered into a subscription ...",
"Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights"
03/06/2023 8-K Other Events  Interactive Data
03/02/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF SESEN BIO, INC.",
"Sesen Bio Stockholders Approve Merger with Carisma Therapeutics Declares Special Dividend in the Aggregate of"
02/28/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results Sesen Bio Board Believes the Pending Merger with Carisma"
02/27/2023 8-K Other Events  Interactive Data
02/14/2023 8-K Quarterly results
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board PHILADELPHIA"
02/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger",
"Sesen Bio Corporate Presentation"
02/01/2023 8-K Quarterly results
01/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS, INCLUDING THE REGISTRATION STATEMENT, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS, AND ALL OTHER RELEVANT DOCUMENTS THAT ARE OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE MATERIALS, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION."
01/30/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Sesen Bio Receives NASDAQ Delisting Notice Company Remains Focused on Significant Benefits of Pending Merger with Carisma Delisting Notice Underscores Potential for Corporate Dissolution"
12/29/2022 8-K Quarterly results
12/23/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
12/12/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update Sesen Bio"
10/04/2022 8-K Other Events  Interactive Data
09/29/2022 8-K Quarterly results
09/21/2022 8-K Acquisition/merger/asset purchase announced
Docs: "AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"CONTINGENT VALUE RIGHTS AGREEMENT",
"FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT",
"FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT",
"Lock-Up Agreement _____ __, 2022",
"Sesen Bio and Carisma Therapeutics Announce Merger Agreement",
"HARNESSING THE POWER OF ENGINEERED MACROPHAGES",
"INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS, INCLUDING THE FORM S-4 AND THE PROXY"
09/08/2022 8-K Other Events  Interactive Data
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "99.1 1 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS IN RE SESEN BIO, INC. DERIVATIVE LITIGATION"
08/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/30/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS IN RE SESEN BIO, INC. DERIVATIVE LITIGATION"
08/17/2022 8-K Quarterly results
08/11/2022 8-K/A Quarterly results
08/08/2022 8-K Quarterly results
07/27/2022 8-K Other Events  Interactive Data
07/21/2022 8-K Quarterly results
07/20/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy